Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 6/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318704 | 0.89 | KDM4E (0.51) | P4HTMNPC1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL17318695 | 0.86 | EGLN1 (0.44) | P4HTMEGLN1NPC1KDM4EALDH1A1 | |
| SCHEMBL20635060 | 0.84 | EGLN1 (0.47) | P4HTMEGLN1NPC1MCHR1RAB9A | |
| SCHEMBL21011226 | 0.84 | NPC1 (0.44) | NPC1KDM4EALDH1A1CYP1A2MCHR1 | |
| SCHEMBL20374925 | 0.82 | SMN1; SMN2 (0.46) | NPC1KDM4EALDH1A1CYP1A2MCHR1 | |
| SCHEMBL22193970 | 0.81 | EGLN1 (0.42) | P4HTMEGLN1 | |
| SCHEMBL15223174 | 0.80 | MCHR1 (0.45) | P4HTMEGLN1NPC1KDM4EALDH1A1 | |
| SCHEMBL22288989 | 0.80 | MCHR1 (0.49) | P4HTMEGLN1NPC1MCHR1RAB9A | |
| SCHEMBL21001618 | 0.80 | EGLN1 (0.57) | P4HTMEGLN1NPC1KDM4EALDH1A1 | |
| SCHEMBL19389656 | 0.78 | MCHR1 (0.47) | EGLN1NPC1KDM4EALDH1A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024178155-A1 | TRANS-CYCLOOCTENE CONJUGATES | TAMBO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2022-04-21 | — | — | US | disclosed |
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2021-12-23 | — | — | US | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| WO-2020141459-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2020-07-09 | — | — | WO | disclosed |
| EP-3152191-B1 | IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS BV (NL) | 2019-05-15 | — | — | EP | disclosed |
| EP-3152191-B1 | IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS BV (NL) | 2019-05-15 | — | — | EP | disclosed |
| WO-2019008441-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2019-01-10 | — | — | WO | disclosed |
| US-9890159-B2 | Process for making duocarmycin prodrugs | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-02-13 | — | — | US | disclosed |
| US-9890159-B2 | Process for making duocarmycin prodrugs | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-02-13 | — | — | US | disclosed |
| WO-2017180813-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| EP-3152191-A1 | IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | Synthon Biopharmaceuticals B.V. (NL) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015185142-A1 | IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185142-A1 | IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118104-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | P4HTM 1903/4885EGLN1 4674/4885NPC1 4849/4885 |
| US-20170145006-A1 | PROCESS FOR MAKING DUOCARMYCIN PRODRUGS | UMPS, UNG, DNASE1 | P4HTM 2190/4885EGLN1 4822/4885NPC1 1597/4885 |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | P4HTM 1903/4885EGLN1 4674/4885NPC1 4849/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | P4HTM 1903/4885EGLN1 4674/4885NPC1 4849/4885 |
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | ANTXR2, VIP, TNFRSF9 | P4HTM 1932/4885EGLN1 4790/4885NPC1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.